Crystagen
EDP Tripeptide · Thymus Immune Bioregulator
Crystagen is a Khavinson bioregulator tripeptide (EDP) identified in thymalin with selective action on thymus tissues. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it enhances immune function by stimulating normal lymphocyte proliferation while inhibiting tumor cell growth. Research shows effectiveness in normalizing immunity in 82% of elderly patients (vs 56% control) and reducing respiratory infections in athletes by doubling HSP gene expression.
Overview
Crystagen is a Khavinson bioregulator tripeptide (EDP) identified in thymalin with selective action on thymus tissues. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it enhances immune function by stimulating normal lymphocyte proliferation while inhibiting tumor cell growth. Research shows effectiveness in normalizing immunity in 82% of elderly patients (vs 56% control) and reducing respiratory infections in athletes by doubling HSP gene expression.
Crystagen works through epigenetic regulation by influencing gene expression and protein synthesis in immune cells. It regulates the synthesis of heat-shock proteins, cytokines, and affects cell differentiation, proliferation, and apoptosis. The EDP peptide enhances spontaneous proliferative activity of normal lymphocytes while inhibiting proliferation of tumor cells (K-562 erythromyelosis). It activates B-cell immune system and thymic epithelial cells (VTEC2.H/S).
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Normalizes immunogram in elderly patients with impaired immunity.
Restores immune function after infectious diseases.
Helps normalize immunity after radiation and chemotherapy exposure.
Increases stress resistance and reduces respiratory infections in athletes.
Doubles expression of heat-shock protein gene HSPA1A.
Inhibits proliferation of K-562 human erythromyelosis tumor cells.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Tripeptide bioregulator
- Chain length
- 3 residues
- Molecular weight
- 359 Da
- Typical dose
- 10-20 mg daily
- Frequency
- Once daily for 10-20 consecutive days
- Cycle length
- 10-20 days per cycle
- Storage
- Capsules: room temperature; Injectable lyophilized: 2-8°C; Reconstituted: 2-8°C refrigerated
Molecular data
- Type
- Tripeptide bioregulator
- Molecular weight
- 359 Da
- Chain length
- 3 residues
EDPDosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Standard protocol | Oral capsules | 10-20 mg | Daily for 10-20 days |
| Maintenance | Oral capsules | 10 mg | 2-3 cycles yearly |
| Athletic support | Oral capsules | 10-20 mg | Daily during training cycles |
| Research protocol | IM or SubQ | 10 mg | Daily for 10 days |
Interactions
Both have immunoprotecting properties; different mechanisms complement each other.
Crystagen (EDP) is derived from thymalin; complementary immune effects.
Often combined in comprehensive anti-aging Khavinson protocols.
Related immune peptides; can be used together.
Quality checklist
- ✓White powder or capsules
- ✓Clear solution if reconstituted
- ✓Proper packaging and labeling
- !Unknown source or purity
- ×Discoloration
- ×Unusual odor
- ×Damaged packaging
What to expect
Safety
- Generally well-tolerated
- Minimal side effects reported
- Allergic reactions
- Unusual immune symptoms
- Active autoimmune flares (consult physician)
- Known hypersensitivity
- Pregnancy or breastfeeding
FAQ
Does Crystagen actually help athletes reduce respiratory infections?
Yes, research shows Crystagen doubled HSP gene expression in athletes and reduced respiratory infections in a study population. By enhancing heat-shock protein production and normalizing IL-6 expression, it strengthens immune resilience during heavy training stress when illness risk is elevated.
What percentage of elderly patients experience immune improvements with Crystagen?
Clinical research found Crystagen normalized immune function (immunogram) in 82% of elderly patients versus only 56% in the control group. This significant difference suggests it effectively reverses age-related immune decline, though results vary individually.
Is Crystagen safe to use if I have an active autoimmune condition?
Crystagen is an immune-stimulating peptide that may exacerbate active autoimmune flares since it enhances lymphocyte proliferation and immune activation. Medical consultation is essential before using, especially during autoimmune disease flares. It's better suited for those with immunodeficiency than autoimmunity.
Can Crystagen help protect immune function after chemotherapy?
Yes, research shows Crystagen effectiveness for normalizing immunity after chemotherapy and radiation exposure. As a thymus-derived immune bioregulator, it supports recovery of lymphocyte populations and immune surveillance that are suppressed by cancer treatments.